NewEdge Wealth LLC Acquires 75,364 Shares of AbbVie Inc. $ABBV

NewEdge Wealth LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 32.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 304,522 shares of the company’s stock after buying an additional 75,364 shares during the quarter. AbbVie comprises approximately 0.9% of NewEdge Wealth LLC’s investment portfolio, making the stock its 15th largest holding. NewEdge Wealth LLC’s holdings in AbbVie were worth $66,011,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its position in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. increased its holdings in AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares in the last quarter. St. Johns Investment Management Company LLC raised its stake in shares of AbbVie by 7.8% in the second quarter. St. Johns Investment Management Company LLC now owns 4,191 shares of the company’s stock worth $778,000 after purchasing an additional 305 shares during the last quarter. Finally, Cullen Frost Bankers Inc. lifted its holdings in shares of AbbVie by 3.1% in the second quarter. Cullen Frost Bankers Inc. now owns 396,225 shares of the company’s stock valued at $73,547,000 after purchasing an additional 11,730 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ABBV shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. Piper Sandler raised their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $251.56.

AbbVie Stock Performance

ABBV stock opened at $228.79 on Thursday. The stock has a fifty day moving average of $224.01 and a 200-day moving average of $221.68. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a market capitalization of $404.36 billion, a price-to-earnings ratio of 96.95, a PEG ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.